Anti-CD20 (Obinutuzumab), Humanized Antibody

Anti-CD20 (Obinutuzumab), Humanized Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is Type II humanized monoclonal antibody that targets CD20 expressed on pre- and mature B lymphocyte cells. The antibody is glycoengineered to increase the binding of CD 64 and CD16 by 7-10 folds and improve antibody-dependent cellular cytotoxicity (ADCC). Additionally, the glycoengineered structure of the antibody helps recruit immune effector cells such as polymorphonuclear neutrophils (PMNs), which when activated, release inflammatory mediators, and promote phagocytosis. A previous study demonstrated that the binding of the antibody to CD20 causes rearrangement of the actin cytoskeleton, which causes the lysosomal compartment to expand. As a result, the lysosomal membrane becomes permeable, causing Cathepsin B to leak into the cytosol. Excessive leakage of Cathepsin B promotes cell death by necrosis. The original drug has been approved by the FDA to treat patients with chronic lymphocytic leukemia (CLL) in combination with Chlorambucil.

Immunogen Sequence:Human CD20

Target Alternative Name:GA-101, GA101, R7159, RG7159, RO5072759, B1, S7, Bp35, CVID5, MS4A2, MS4A1, LEU-16

Species Reactivities:Human

Tag Line:The biosimilar is a type II humanized monoclonal antibody that targets CD20 and induces B-cell lysis via antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:In vitro studies

Handling:The antibody solution should be gently mixed before use.